Suchergebnisse

Jiapeng Xu,1,* Yu Zhang,1,* Qing You,1 Hongbing Fu,1 Xiaokai Zhao,2 Kai Lu,2 Ronglin Yan,1 Dejun Yang1 1Department of Gastrointestinal Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China; 2Shanghai Yunying Medical Technology Co.Ltd, Shanghai 201600, People's Republic of China*These authors contributed equally to this workCorrespondence: Ronglin Yan; Dejun YangDepartment of Gastrointestinal Surgery, Changzheng Hospital, Second Military Medical University, No. 415 Fengyang Road, Huangpu District, Shanghai 200003, People's Republic of ChinaEmail yanronglin@smmu.edu.cn; yangdejun@smmu.edu.cnIntroduction: It is worldwide accepted that lncRNA PTCSC3 is a tumor suppressor in glioma and thyroid cancer, whereas its role in the recurrence of gastric cancer is unknown.Patients and Methods: We recruited 80 GC patients (46 males and 34 females, 44 to 68 years, 56.3± 6.7 years) in our study. Two human GC cell lines AGS and SNU-1 were transfected with PTCSC3 and HOXA11-AS expression vectors. Then, qPCR was used to detect the level of relative mRNA. Both invasion and migration assays were performed to detect the effect of the lncRNA on gastric cancer cell motility.Results: In the present study, we showed that PTCSC3 was downregulated in plasma of gastric cancer patients than in plasma of healthy controls. Follow-up study indicated that PTCSC3 was further downregulated in patients with distant-recurrence but not in patients with local recurrence only or non-recurrence. LncRNA HOXA11-AS was upregulated in plasma of gastric cancer cells than in plasma of healthy controls and was inversely correlated with PTCSC3 in plasma of gastric cancer patients. PTCSC3 overexpression mediated the downregulation of HOXA11-AS in gastric cancer cells, while HOXA11-AS overexpression failed to significantly affect PTCSC3. PTCSC3 overexpression led to inhibited, while HOXA11-AS overexpression led to promoted migration and invasion of gastric cancer cells. In addition, HOXA11-AS overexpression reduced the effects of PTCSC3 overexpression.Discussion: Therefore, lncRNA PTCSC3 alleviates in the postoperative distant recurrence of gastric cancer possible by suppression of HOXA11-AS.Keywords: PTCSC3, gastric cancer, distant recurrence, HOXA11-AS

Xin Zhang,1,* Hejing Huang,2,* Ziran Wei,1,* Zhenxin Zhu,1 Dejun Yang,1 Hongbing Fu,1 Jiapeng Xu,1 Zunqi Hu,1 Yu Zhang,1 Qing You,1 Xin Huang,1 Ronglin Yan,1 Weimin Wang,1 Qingping Cai1 1Department of Gastrointestinal Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China; 2Department of Ultrasound, Changzheng Hospital, Second Military Medical University, Shanghai, People's Republic of China*These authors contributed equally to this workCorrespondence: Qingping Cai; Ronglin Yan Tel +86-21-81885601; +86-21-81885603Fax +86-21-81886000Email caiqingping@smmu.edu.cn; yanronglin@smmu.edu.cnBackground: What is the optimal neoadjuvant chemotherapy (NAC) regimen for locally advanced gastric cancer (LAGC) remains debatable. The objective of this study was to compare the efficacy of docetaxel+oxaliplatin+S-1 (DOS) vs oxaliplatin+S-1 (SOX) as NAC for LAGC.Methods: Data of 248 LAGC patients who received either DOS or SOX as NAC in our hospital between January 2010 and January 2018 were reviewed retrospectively. Propensity score matched (PSM) analysis was applied to minimize the selection bias in both groups. Prognostic factors were screened by univariate and multivariate Cox regression analyses.Results: Of the 248 LAGC patients included, 180 patients were subjected to the PSM analysis. Patients in DOS group showed a better tumor response to NAC, higher radical resection rate and R0 resection rate than those in SOX group. The overall survival (OS) rate in DOS group was better than that in SOX group, although the overall incidence of Grade 3/4 NAC-related toxicity in DOS group was higher, as represented by leukopenia and neutropenia. Multivariate analysis revealed that the NAC regimen, cTNM stage and the R0 resection rate were independent prognostic factors. In addition, patients with TLND less than 16 population showed a worse OS rate. Subgroup analysis indicated that patients benefited from the addition of docetaxel regardless of the clinical T stage, but those with high clinical N stages (N2-3) did not.Conclusion: DOS is a safe and feasible NAC regimen for LAGC, which is worth popularizing in clinical practice.Keywords: locally advanced gastric cancer, neoadjuvant chemotherapy, radical gastrectomy, propensity score matched analysis, docetaxel